We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01096173
First Posted: March 30, 2010
Last Update Posted: April 11, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
The VA Western New York Healthcare System
Buffalo Institute For Medical Research
Information provided by:
Pulmatrix Inc.
  Purpose
This study is intended to be an evaluation of the properties of human sputum collected from patients with COPD. It is hypothesized that cationic airway lining modulators will have beneficial effects on the rheological properties of sputum derived from patients with COPD. Approximately 10 patients with COPD will collect sputum at home for 5 days. Samples will be collected and tested in laboratory tests.

Condition
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Official Title: Determination of the in Vitro Effects of CALM on COPD Sputum

Resource links provided by NLM:


Further study details as provided by Pulmatrix Inc.:

Biospecimen Retention:   None Retained
Sputum samples

Estimated Enrollment: 10
Study Start Date: April 2010
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Outpatient clinic setting
Criteria

Inclusion Criteria:

  1. Clinical and spirometric diagnosis of COPD
  2. Smoking history of at least 10 pack yrs
  3. Sputum production of greater than 2 tablespoons per day by patient report.

Exclusion Criteria:

  1. a primary diagnosis of asthma or bronchiectasis
  2. a COPD exacerbation within 4 weeks
  3. Inability to comply with study procedures.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01096173


Locations
United States, New York
VA WNY Healthcare System
Buffalo, New York, United States, 14215
Sponsors and Collaborators
Pulmatrix Inc.
The VA Western New York Healthcare System
Buffalo Institute For Medical Research
Investigators
Principal Investigator: Sanjay Sethi, MD Va Western NY Healthcare, Buffalo Institute for Medical Research
  More Information

Responsible Party: Dr. Sanjay Sethi, MD, VA of Western NY Healthcare System, Buffalo Institute for Medical Research
ClinicalTrials.gov Identifier: NCT01096173     History of Changes
Other Study ID Numbers: PUL_VABUF_01
First Submitted: March 25, 2010
First Posted: March 30, 2010
Last Update Posted: April 11, 2011
Last Verified: April 2011

Keywords provided by Pulmatrix Inc.:
Sputum
chronic obstructive pulmonary disease

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases